期刊
PHARMACOLOGY & THERAPEUTICS
卷 192, 期 -, 页码 74-87出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2018.07.004
关键词
Cytochrome P450; 20-HETE; Hypertension; Myocardial infarction; Angiogenesis; Vascular remodeling; Heart failure
资金
- National Heart, Lung, and Blood Institute [R01-HL093052, PO1-HL034300, 1RO1-HL139793]
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL139793, P01HL034300, R01HL093052] Funding Source: NIH RePORTER
20-HETE, the to omega-hydroxylation product of arachidonic acid catalyzed by enzymes of the cytochrome P450 (CYP) 4A and 4F gene families, is a bioactive lipid mediator with potent effects on the vasculature including stimulation of smooth muscle cell contractility, migration and proliferation as well as activation of endothelial cell dysfunction and inflammation. Clinical studies have shown elevated levels of plasma and urinary 20-HETE in human diseases and conditions such as hypertension, obesity and metabolic syndrome, myocardial infarction, stroke, and chronic kidney diseases. Studies of polymorphic associations also suggest an important role for 20-HETE in hypertension, stroke and myocardial infarction. Animal models of increased 20-HETE production are hypertensive and are more susceptible to cardiovascular injury. The current review summarizes recent findings that focus on the role of 20-HETE in the regulation of vascular and cardiac function and its contribution to the pathology of vascular and cardiac diseases. (C) 2018 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据